Table of Contents
Introduction
What is this report about?
Who is the target reader?
How to use this report
Definitions
Top Emerging Countries Generics
Industry Outlook
Generics in South Africa
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Brazil
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in China
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in India
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Generics in Mexico
Market Overview
Market Data
Market Segmentation
Market outlook
Five forces analysis
Macroeconomic indicators
Company Profiles
Leading companies
Appendix
Methodology
About MarketLine

List of Tables
Table 1: Top 5 emerging countries generics industry, revenue ($bn), 2012-21
Table 2: Top 5 emerging countries generics industry, revenue ($bn), 2012-16
Table 3: Top 5 emerging countries generics industry forecast, revenue ($bn), 2016-21
Table 4: South Africa generics market value: $ billion, 2012–16
Table 5: South Africa generics market volume: % of total pharma volume, 2012–16
Table 6: South Africa generics market geography segmentation: $ billion, 2016
Table 7: South Africa generics market value forecast: $ billion, 2016–21
Table 8: South Africa generics market volume forecast: % of total pharma volume, 2016–21
Table 9: South Africa size of population (million), 2012–16
Table 10: South Africa gdp (constant 2005 prices, $ billion), 2012–16
Table 11: South Africa gdp (current prices, $ billion), 2012–16
Table 12: South Africa inflation, 2012–16
Table 13: South Africa consumer price index (absolute), 2012–16
Table 14: South Africa exchange rate, 2012–16
Table 15: Brazil generics market value: $ billion, 2012–16
Table 16: Brazil generics market volume: % of total pharma volume, 2012–16
Table 17: Brazil generics market geography segmentation: $ billion, 2016
Table 18: Brazil generics market value forecast: $ billion, 2016–21
Table 19: Brazil generics market volume forecast: % of total pharma volume, 2016–21
Table 20: Brazil size of population (million), 2012–16
Table 21: Brazil gdp (constant 2005 prices, $ billion), 2012–16
Table 22: Brazil gdp (current prices, $ billion), 2012–16
Table 23: Brazil inflation, 2012–16
Table 24: Brazil consumer price index (absolute), 2012–16
Table 25: Brazil exchange rate, 2012–16
Table 26: China generics market value: $ billion, 2012–16
Table 27: China generics market volume: % of total pharma volume, 2012–16
Table 28: China generics market geography segmentation: $ billion, 2016
Table 29: China generics market value forecast: $ billion, 2016–21
Table 30: China generics market volume forecast: % of total pharma volume, 2016–21
Table 31: China size of population (million), 2012–16
Table 32: China gdp (constant 2005 prices, $ billion), 2012–16
Table 33: China gdp (current prices, $ billion), 2012–16
Table 34: China inflation, 2012–16
Table 35: China consumer price index (absolute), 2012–16
Table 36: China exchange rate, 2012–16
Table 37: India generics market value: $ billion, 2012–16
Table 38: India generics market volume: % of total pharma volume, 2012–16
Table 39: India generics market geography segmentation: $ billion, 2016
Table 40: India generics market value forecast: $ billion, 2016–21
Table 41: India generics market volume forecast: % of total pharma volume, 2016–21
Table 42: India size of population (million), 2012–16
Table 43: India gdp (constant 2005 prices, $ billion), 2012–16
Table 44: India gdp (current prices, $ billion), 2012–16
Table 45: India inflation, 2012–16
Table 46: India consumer price index (absolute), 2012–16
Table 47: India exchange rate, 2012–16
Table 48: Mexico generics market value: $ billion, 2012–16
Table 49: Mexico generics market volume: % of total pharma volume, 2012–16
Table 50: Mexico generics market geography segmentation: $ billion, 2016
Table 51: Mexico generics market value forecast: $ billion, 2016–21
Table 52: Mexico generics market volume forecast: % of total pharma volume, 2016–21
Table 53: Mexico size of population (million), 2012–16
Table 54: Mexico gdp (constant 2005 prices, $ billion), 2012–16
Table 55: Mexico gdp (current prices, $ billion), 2012–16
Table 56: Mexico inflation, 2012–16
Table 57: Mexico consumer price index (absolute), 2012–16
Table 58: Mexico exchange rate, 2012–16
Table 59: Adcock Ingram Holdings Limited: key facts
Table 60: Adcock Ingram Holdings Limited: key financials ($)
Table 61: Adcock Ingram Holdings Limited: key financials (ZAR)
Table 62: Adcock Ingram Holdings Limited: key financial ratios
Table 63: Aspen Pharmacare Holdings Ltd: key facts
Table 64: Aspen Pharmacare Holdings Ltd: key financials ($)
Table 65: Aspen Pharmacare Holdings Ltd: key financials (ZAR)
Table 66: Aspen Pharmacare Holdings Ltd: key financial ratios
Table 67: O Ache Laboratorios Farmaceuticos S.A.: key facts
Table 68: EMS Sigma Pharma: key facts
Table 69: Eurofarma Laboratórios S.A.: key facts
Table 70: Sanofi SA: key facts
Table 71: Sanofi SA: key financials ($)
Table 72: Sanofi SA: key financials (€)
Table 73: Sanofi SA: key financial ratios
Table 74: China Grand Pharmaceutical and Healthcare Holdings Limited: key facts
Table 75: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials ($)
Table 76: China Grand Pharmaceutical and Healthcare Holdings Limited: key financials (CNY)
Table 77: China Grand Pharmaceutical and Healthcare Holdings Limited: key financial ratios
Table 78: Mylan Inc.: key facts
Table 79: Mylan Inc.: key financials ($)
Table 80: Mylan Inc.: key financial ratios
Table 81: Sandoz International GmbH: key facts
Table 82: Aurobindo Pharma Limited: key facts
Table 83: Aurobindo Pharma Limited: key financials ($)
Table 84: Aurobindo Pharma Limited: key financials (Rs.)
Table 85: Aurobindo Pharma Limited: key financial ratios
Table 86: Cipla Limited: key facts
Table 87: Cipla Limited: key financials ($)
Table 88: Cipla Limited: key financials (Rs.)
Table 89: Cipla Limited: key financial ratios
Table 90: Lupin Limited: key facts
Table 91: Lupin Limited: key financials ($)
Table 92: Lupin Limited: key financials (Rs.)
Table 93: Lupin Limited: key financial ratios
Table 94: Sun Pharmaceutical Industries Ltd.: key facts
Table 95: Sun Pharmaceutical Industries Ltd.: key financials ($)
Table 96: Sun Pharmaceutical Industries Ltd.: key financials (Rs.)
Table 97: Sun Pharmaceutical Industries Ltd.: key financial ratios
Table 98: Apotex, Inc.: key facts
Table 99: Teva Pharmaceutical Industries Limited: key facts
Table 100: Teva Pharmaceutical Industries Limited: key financials ($)
Table 101: Teva Pharmaceutical Industries Limited: key financial ratios

List of Figures
Figure 1: Top 5 emerging countries generics industry, revenue ($bn), 2012-21
Figure 2: Top 5 emerging countries generics industry, revenue ($bn), 2012-16
Figure 3: Top 5 emerging countries generics industry forecast, revenue ($bn), 2016-21
Figure 4: South Africa generics market value: $ billion, 2012–16
Figure 5: South Africa generics market volume: % of total pharma volume, 2012–16
Figure 6: South Africa generics market geography segmentation: % share, by value, 2016
Figure 7: South Africa generics market value forecast: $ billion, 2016–21
Figure 8: South Africa generics market volume forecast: % of total pharma volume, 2016–21
Figure 9: Forces driving competition in the generics market in South Africa, 2016
Figure 10: Drivers of buyer power in the generics market in South Africa, 2016
Figure 11: Drivers of supplier power in the generics market in South Africa, 2016
Figure 12: Factors influencing the likelihood of new entrants in the generics market in South Africa, 2016
Figure 13: Factors influencing the threat of substitutes in the generics market in South Africa, 2016
Figure 14: Drivers of degree of rivalry in the generics market in South Africa, 2016
Figure 15: Brazil generics market value: $ billion, 2012–16
Figure 16: Brazil generics market volume: % of total pharma volume, 2012–16
Figure 17: Brazil generics market geography segmentation: % share, by value, 2016
Figure 18: Brazil generics market value forecast: $ billion, 2016–21
Figure 19: Brazil generics market volume forecast: % of total pharma volume, 2016–21
Figure 20: Forces driving competition in the generics market in Brazil, 2016
Figure 21: Drivers of buyer power in the generics market in Brazil, 2016
Figure 22: Drivers of supplier power in the generics market in Brazil, 2016
Figure 23: Factors influencing the likelihood of new entrants in the generics market in Brazil, 2016
Figure 24: Factors influencing the threat of substitutes in the generics market in Brazil, 2016
Figure 25: Drivers of degree of rivalry in the generics market in Brazil, 2016
Figure 26: China generics market value: $ billion, 2012–16
Figure 27: China generics market volume: % of total pharma volume, 2012–16
Figure 28: China generics market geography segmentation: % share, by value, 2016
Figure 29: China generics market value forecast: $ billion, 2016–21
Figure 30: China generics market volume forecast: % of total pharma volume, 2016–21
Figure 31: Forces driving competition in the generics market in China, 2016
Figure 32: Drivers of buyer power in the generics market in China, 2016
Figure 33: Drivers of supplier power in the generics market in China, 2016
Figure 34: Factors influencing the likelihood of new entrants in the generics market in China, 2016
Figure 35: Factors influencing the threat of substitutes in the generics market in China, 2016
Figure 36: Drivers of degree of rivalry in the generics market in China, 2016
Figure 37: India generics market value: $ billion, 2012–16
Figure 38: India generics market volume: % of total pharma volume, 2012–16
Figure 39: India generics market geography segmentation: % share, by value, 2016
Figure 40: India generics market value forecast: $ billion, 2016–21
Figure 41: India generics market volume forecast: % of total pharma volume, 2016–21
Figure 42: Forces driving competition in the generics market in India, 2016
Figure 43: Drivers of buyer power in the generics market in India, 2016
Figure 44: Drivers of supplier power in the generics market in India, 2016
Figure 45: Factors influencing the likelihood of new entrants in the generics market in India, 2016
Figure 46: Factors influencing the threat of substitutes in the generics market in India, 2016
Figure 47: Drivers of degree of rivalry in the generics market in India, 2016
Figure 48: Mexico generics market value: $ billion, 2012–16
Figure 49: Mexico generics market volume: % of total pharma volume, 2012–16
Figure 50: Mexico generics market geography segmentation: % share, by value, 2016
Figure 51: Mexico generics market value forecast: $ billion, 2016–21
Figure 52: Mexico generics market volume forecast: % of total pharma volume, 2016–21
Figure 53: Forces driving competition in the generics market in Mexico, 2016
Figure 54: Drivers of buyer power in the generics market in Mexico, 2016
Figure 55: Drivers of supplier power in the generics market in Mexico, 2016
Figure 56: Factors influencing the likelihood of new entrants in the generics market in Mexico, 2016
Figure 57: Factors influencing the threat of substitutes in the generics market in Mexico, 2016
Figure 58: Drivers of degree of rivalry in the generics market in Mexico, 2016
Figure 59: Adcock Ingram Holdings Limited: revenues & profitability
Figure 60: Adcock Ingram Holdings Limited: assets & liabilities
Figure 61: Aspen Pharmacare Holdings Ltd: revenues & profitability
Figure 62: Aspen Pharmacare Holdings Ltd: assets & liabilities
Figure 63: Sanofi SA: revenues & profitability
Figure 64: Sanofi SA: assets & liabilities
Figure 65: China Grand Pharmaceutical and Healthcare Holdings Limited: revenues & profitability
Figure 66: China Grand Pharmaceutical and Healthcare Holdings Limited: assets & liabilities
Figure 67: Mylan Inc.: revenues & profitability
Figure 68: Mylan Inc.: assets & liabilities
Figure 69: Aurobindo Pharma Limited: revenues & profitability
Figure 70: Aurobindo Pharma Limited: assets & liabilities
Figure 71: Cipla Limited: revenues & profitability
Figure 72: Cipla Limited: assets & liabilities
Figure 73: Lupin Limited: revenues & profitability
Figure 74: Lupin Limited: assets & liabilities
Figure 75: Sun Pharmaceutical Industries Ltd.: revenues & profitability
Figure 76: Sun Pharmaceutical Industries Ltd.: assets & liabilities
Figure 77: Teva Pharmaceutical Industries Limited: revenues & profitability
Figure 78: Teva Pharmaceutical Industries Limited: assets & liabilities